iShares Nasdaq-100 ex Top 30 ETF
QNXT - ETF AI Analysis
Top Page
iShares Nasdaq-100 ex Top 30 ETF (QNXT)
QNXT’s rating suggests it is a solid but not top-tier ETF, supported by several strong, growing companies. Key holdings like ASML and Qualcomm boost the fund’s quality through robust financial performance, positive momentum, and strategic growth initiatives, while other leaders such as Gilead and Vertex add stability with strong earnings and focused pipelines. However, weaker names like Starbucks and Booking Holdings, which face high leverage, valuation concerns, and bearish technical trends, along with the fund’s meaningful exposure to tech and growth-oriented stocks, introduce risk if market conditions turn against these sectors.
QNXT vs. SPDR S&P 500 ETF (SPY)
- AUM
- 27.71M
- Region
- North America
- Expense Ratio
- 0.20%
- Beta
- 1.06
- Issuer
- iShares
- Inception Date
- Oct 23, 2024
- Dividend Yield
- 0.71%
- Asset Class
- Equity
- Index Tracked
- Nasdaq-100 ex Top 30 Index - Benchmark TR Net
QNXT Summary
QNXT is an ETF that follows the Nasdaq-100 ex Top 30 Index, meaning it invests in many of the next-tier large companies in the Nasdaq, but leaves out the 30 biggest names. It mainly holds U.S. stocks in technology, healthcare, and consumer businesses. Well-known companies in the fund include Shopify and Qualcomm. Someone might invest in QNXT to seek growth from innovative firms while avoiding heavy concentration in the largest tech giants. A key risk is that it is still heavily tied to the stock market and tech-related sectors, so its value can go up and down significantly.
How much will it cost me?
This ETF has an expense ratio of 0.20%, which means you’ll pay about $2 per year for every $1,000 you invest. That’s slightly higher than the cheapest index ETFs, because it tracks a more specialized version of the Nasdaq-100 rather than a very broad, plain-vanilla market index.
What would affect this ETF?
This ETF is heavily tilted toward U.S. technology, healthcare, and consumer companies like Shopify, Qualcomm, and Gilead, so it could benefit if innovation, online spending, and medical advances continue to grow and if interest rates eventually ease, supporting higher stock prices. On the downside, it may be hurt by rising interest rates, slower U.S. economic growth, tighter tech and healthcare regulations, or weaker consumer spending, and because it excludes the largest Nasdaq names, it could lag if those mega-cap stocks strongly outperform.
QNXT Top 10 Holdings
QNXT leans heavily into U.S. tech and healthcare, with a bench of “next-tier” innovators doing most of the heavy lifting. Analog Devices and ASML are key tech engines, generally rising but occasionally hitting speed bumps when valuations look stretched. Western Digital has been a standout, surging on renewed demand and giving the fund extra torque. On the healthcare side, Gilead and Vertex are steady climbers, helping smooth volatility. Offsetting that strength, Qualcomm and Intuitive Surgical have been more mixed, at times losing steam and trimming some of the fund’s momentum.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Gilead Sciences | 3.97% | $1.10M | $208.48B | 34.25% | 78Outperform | |
| Analog Devices | 3.78% | $1.05M | $192.84B | 67.55% | 78Outperform | |
| Qualcomm | 3.54% | $981.71K | $184.54B | -1.16% | 80Outperform | |
| Shopify | ― | ― | ― | ― | 77Outperform | |
| Intuitive Surgical | 2.96% | $819.95K | $153.77B | -21.56% | 78Outperform | |
| ASML Holding | 2.68% | $742.57K | $563.74B | 46.60% | 81Outperform | |
| Vertex Pharmaceuticals | 2.62% | $726.03K | $136.56B | 23.95% | 78Outperform | |
| Automatic Data Processing | 2.33% | $645.40K | $122.35B | 21.73% | 70Outperform | |
| Starbucks | 2.33% | $645.28K | $121.35B | 23.14% | 56Neutral | |
| Booking Holdings | 2.31% | $639.16K | $118.68B | -21.40% | 63Neutral |
QNXT Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For QNXT, the sentiment is Negative. The current price of 30.67 is below the 20-day moving average (MA) of 30.79, below the 50-day MA of 30.83, and above the 200-day MA of 29.74, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 48.53 is Neutral, neither overbought nor oversold. The STOCH value of 79.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QNXT.
QNXT Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $30.67 | $34.00(10.86% Upside) | $27.71M | 0.20% | 72Outperform | |
| $29.50 | $36.70(24.42% Upside) | $100.71M | 1.35% | 73Outperform | |
| $28.31 | $34.21(20.81% Upside) | $93.61M | 1.00% | 73Outperform | |
| $54.06 | $66.64(23.26% Upside) | $87.06M | 0.21% | 73Outperform | |
| $80.92 | $98.14(21.28% Upside) | $85.41M | 0.09% | 74Outperform | |
| $69.80 | $79.80(14.32% Upside) | $80.07M | 0.19% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| QNXT | iShares Nasdaq-100 ex Top 30 ETF | 30.67 | 4.09 | 15.37% | |
| HAWG | HCM Hedged Equity ETF | 29.50 | -0.76 | -2.52% | |
| PRMR | PeakShares RMR Prime Equity ETF | 28.31 | 3.33 | 13.34% | |
| NULC | Nuveen ESG Large-Cap ETF | 54.06 | 7.63 | 16.43% | |
| SPXE | ProShares S&P 500 Ex-Energy ETF | 80.92 | 9.67 | 13.58% | |
| QARP | Xtrackers Russell 1000 US Quality at a Reasonable Price ETF | 69.80 | 13.40 | 23.75% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
